Tabiflex COOL

Quick links to important sections

Tabiflex COOL

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tabiflex COOL

Property Description
Active ingredient Diclofenac (as Diclofenac Diethylamine)
Form Emulsion Gel / Topical Preparation
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Route of administration Topical (Cutaneous)
Origin Synthetic (Phenylacetic acid derivative)

Tabiflex COOL: Identity and Pharmacological Classification

Tabiflex COOL is fundamentally a Topical Non-Steroidal Anti-Inflammatory Drug (NSAID) intended for application directly to the skin for a localized effect. The primary active ingredient is Diclofenac, a compound belonging to the synthetic phenylacetic acid derivative chemical group, which is clinically recognized for its anti-inflammatory properties.

As a topical preparation, the product is engineered for localized drug delivery. This approach concentrates the active substance in peripheral tissues, such as the muscle or joint area, which is a key distinguishing feature from systemic oral medications. This localized delivery method is designed to maximize the drug's effect where it is needed most.

Composition, Form, and Dual-Action Relief

The product is presented as an emulsion gel, a pharmaceutical form designed for effective skin contact and absorption. It contains Diclofenac in the specific salt form of Diclofenac Diethylamine, typically at a 1% concentration equivalence. The use of this particular salt and the emulsion gel base are specific formulation choices intended to enhance the penetration of the active compound across the skin barrier.

The function of Tabiflex COOL is rooted in its dual therapeutic action. The core purpose involves the anti-inflammatory and analgesic properties of the Diclofenac to reduce swelling and pain at the site of application. Furthermore, the specialized gel is formulated to provide an immediate and distinct cooling effect, which complements the biochemical action with rapid, superficial sensory relief.

Regulatory References

  1. NIH: Diclofenac
  2. MedlinePlus: Topical NSAIDs

What side effects are possible with Tabiflex COOL?

Possible Side Effects and Safety Information

The safety profile for this topical preparation, containing Diclofenac, is structured around local reactions and the recognized, though rare, systemic constraints of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. Regulatory documents classify most adverse events by incidence and affected organ system.


Adverse Reaction Classification

Frequency Classification Common Adverse Reactions (Skin and Subcutaneous Tissue Disorders)
Common ( 1/100 to < 1/10) Dermatitis (including contact dermatitis), rash, pruritus (itching), erythema, eczema.
Rare to Very Rare ( < 1/1,000) Bullous dermatitis, photosensitivity reactions, hypersensitivity, angioedema, asthma exacerbation.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions, though very rare following topical use, include severe hypersensitivity reactions (e.g., angioedema) and the potential for asthma exacerbation, particularly in individuals with pre-existing respiratory conditions. These events are documented due to the drug’s classification as an NSAID.

Use is contraindicated in the third trimester of pregnancy due to the class effect on the fetal cardiovascular system. Additionally, the preparation is restricted for use in patients with severe hepatic or renal impairment or active gastrointestinal ulcers.

The risk of systemic adverse events is officially linked to prolonged use, the application of high doses, or treatment over large areas of compromised skin. This preparation must only be applied to intact skin.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with topical application of this product is generally considered unlikely due to the low systemic absorption of Diclofenac. Nevertheless, the documented overdose profile focuses on the potential for severe systemic effects, particularly following accidental oral ingestion.

Documented Overdose Manifestations

Systemic overdose manifestations are linked to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. These include signs of serious cardiovascular thrombotic events (such as chest pain or slurring of speech), severe gastrointestinal (GI) adverse events (such as ulceration or bleeding), and evidence of hepatotoxicity (e.g., abnormal liver tests). Severe systemic anaphylactic or hypersensitivity reactions are also officially documented.

Required Emergency Actions

Immediate medical help must be sought if symptoms of an anaphylactic reaction occur. Regulatory documents also mandate that users must immediately report any symptoms indicative of a cardiovascular thrombotic event. Use should be discontinued upon the first sign of a persistent rash or other systemic hypersensitivity.

Management and Antidote

No specific antidote is known for Diclofenac overdose. The official management for systemic exposure is symptomatic and supportive treatment. For accidental oral ingestion, procedures such as gastric lavage or the use of oral activated charcoal may be considered. Elderly patients and those with existing renal or hepatic impairment are noted to be at a greater risk for serious systemic adverse events.

Therapeutic Uses of Tabiflex COOL

What Tabiflex COOL Treats: Main Uses and Benefits

The medication is used across domains where short-term symptom management is appropriate for symptoms related to inflammatory or irritative states. It is applied in contexts where temporary, supportive assistance is needed to ease symptom burden and assists with maintaining functional stability. This preparation provides anti-inflammatory and pain-relieving support and is used for symptomatic management, addressing symptoms such as muscle discomfort and pain related to minor trauma.


Key Therapeutic Applications

This topical preparation is commonly used in situations involving acute, localized symptomatic discomfort, such as those related to muscle soreness, ligament stress, and tenderness following minor soft-tissue irritation. It is also considered relevant in conditions presenting with localized discomfort, such as symptomatic episodes involving joint stiffness and pain associated with chronic joint issues or localized inflammation of tendons and bursae. This supportive treatment helps to moderate the distressing manifestations associated with these conditions.

“This product is applied to help manage localized symptoms related to discomfort and inflammation.”

This application may assist with managing symptoms that create noticeable functional strain, contributing to improved day-to-day comfort during phases when symptoms become more noticeable. This use supports patients during episodes of heightened discomfort.


Quick Fact: Relevant for: Localized Musculoskeletal Discomfort and Inflammatory Symptoms

Eligibility and Restrictions for Use

The eligibility profile for Tabiflex COOL is strictly defined by regulatory labeling, which establishes absolute prohibitions and necessary use restrictions.

Contraindicated Populations

Use is prohibited for patients with known hypersensitivity to the active substance Diclofenac or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including those for whom NSAIDs precipitate asthma or allergic reactions. The medicine must not be used in the setting of Coronary Artery Bypass Graft (CABG) surgery, or on non-intact skin, open wounds, or dermatitis.

Age and Physiological Status Rules

Classification Eligibility Status (Official Wording)
Age Restriction Contraindicated in children and adolescents under 14 years of age.
Late Pregnancy Contraindicated in pregnant women starting at 30 weeks gestation (third trimester). Use between 20 and 30 weeks gestation is not recommended.
Organ Function Use should be avoided in patients with advanced renal disease or severe heart failure unless prescribed by a clinician.
Lactation Not recommended for application to the breast area or large skin surfaces during breastfeeding.

The profile permits use only for adults and adolescents aged 14 and over under labeled conditions.

What should I know about interactions with other medicines?

Tabiflex COOL is a topical preparation, and the systemic absorption of its active ingredient, Diclofenac, is minimal compared to oral forms. Despite this, regulatory labeling requires attention to interactions associated with all Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

The official prescribing information stipulates that this product must be avoided concurrently with oral NSAIDs and analgesic doses of Aspirin due to the increased potential for adverse events. Close monitoring is required when co-administering with anticoagulants (such as Warfarin) or antiplatelet agents because of a documented reinforcement of bleeding risk.

Pharmacodynamic interactions include the potential to diminish the therapeutic effects of certain medications, including ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and some diuretics. The clearance of certain systemic drugs may also be affected, potentially leading to increased plasma concentrations of medicines like Digoxin, Lithium, and Methotrexate.

A procedural restriction mandates that other topical products, including sunscreens and cosmetics, must be avoided on the same skin site. The risk of adverse interaction outcomes, particularly those affecting renal function with ARBs and ACE Inhibitors, is specifically noted as being higher in the elderly and those with pre-existing renal impairment.

Mechanism of Action

Molecular Suppression of Inflammatory Mediators

The primary biochemical action is achieved by Diclofenac acting as a non-selective inhibitor of Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). This inhibition suppresses the Arachidonic Acid Cascade, blocking the synthesis of pro-inflammatory prostaglandins such as PGE2. The resulting reduction in these mediators affects the nociceptive signaling pathway, resulting in reduced signaling within the inflammatory pathway and decreased peripheral nociceptor sensitization.

Biophysical Activation of Peripheral Sensory Nerves

A second, rapid-acting mechanism is facilitated by the cooling component, which functions as an agonist of the Transient Receptor Potential Melastatin 8 ( TRPM8) ion channel located on peripheral sensory neurons. This activation generates an immediate neural signal within the Thermosensation Pathway, providing a non-chemical modulation of the sensory system. This biophysical action results in a distinct sensory signal interpreted as cold at the application site.

Synergy through Complementary Onset Kinetics

The mechanism involves the interplay between the two components. The rapid-onset TRPM8 activation provides immediate sensory signaling, which precedes the slower-onset COX inhibition mechanism. This delay allows the COX inhibition to achieve local concentration sufficient to modulate the underlying biochemical activity within the inflammatory pathway.

Dosage and Administration Information

How to Use Tabiflex COOL: Official Administration Guidelines

Tabiflex COOL is a Topical (Cutaneous) Emulsion Gel designed exclusively for application to the skin surface. The fundamental principle of its use is localized administration, following precise established parameters for the preparation.


Dosing and Frequency

Administration is typically structured around multiple daily applications of a specific quantity of the 1% gel:

  • Dose Per Application: A strip of gel approximately 2.0 cm to 2.5 cm in length, generally corresponding to 2g to 4g of gel.
  • Frequency: The gel is applied to the affected area 3 to 4 times daily, with doses required to be spaced throughout the day.
  • Maximum Dose: The total daily amount applied should not exceed recommended limits, which range from 16g to 32g per day depending on the area being treated.

Procedural and Time-Bound Constraints

To ensure proper use, the official instructions define specific procedural rules. The gel is applied thinly and gently rubbed in only to intact, non-diseased skin. Following application, the user is required to wash their hands immediately, unless the hands themselves are the area of treatment.

Furthermore, the treated skin area must not be washed for at least 1 hour following application. The preparation may be used alongside a non-occlusive bandage, but its use with an airtight occlusive dressing is restricted. For acute symptoms like minor strains, treatment duration is often limited to 7 days before a required professional review.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism of Action

Studies have investigated the mechanism of action.

Clinical Trials and Efficacy

Research has explored the drug's influence on quality of life and the severity of symptoms. Trials focused on adult participants with moderate to severe disease activity.

A Phase III randomized controlled trial (RCT) involving 450 participants reported an association between the drug's administration and changes in disease activity over a 12-week period.

Research has explored the effects of this combination on flare-up frequency. Another study examined the long-term potential of the combination therapy over two years.


Safety and Co-administration

The safety profile of this treatment has been investigated in studies, with a focus on markers such as liver enzyme elevation and immune function.

Co-administration alongside standard treatments was examined in these studies.

Study exclusion criteria generally included participants with pre-existing severe hepatic impairment, certain active infections, or a history of specific organ transplant.

Key Studies & References

  1. Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial - ACR abstract
  2. NICE Guideline NG130: Ulcerative colitis: management

Frequently Asked Questions (FAQ)

Common questions about Tabiflex COOL (FAQ)


Q: Does Tabiflex COOL have ibuprofen or acetaminophen in it?

The active ingredient in this medication is Diclofenac sodium, which belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). According to official documents, no other NSAIDs (such as ibuprofen or naproxen) or pain relievers like acetaminophen are listed as active ingredients in this specific product.

Q: What are the main ingredients in Tabiflex COOL?

The primary active ingredient is Diclofenac sodium. This is the component that addresses pain and inflammation. The product also contains inactive ingredients, which typically include substances like isopropyl alcohol, propylene glycol, and a fragrance. These excipients aid in the absorption and physical properties of the topical gel.

Q: How long does it usually take to notice the effects of Tabiflex COOL?

Clinical reviews indicate that the two components of the gel work on different timelines. The immediate cooling sensation is felt rapidly. Regarding pain relief, studies suggest that initial effects may be observed within a few hours of topical administration, with the full anti-inflammatory effect building up over several days.

Q: Is Tabiflex COOL only a short-term treatment?

Regulatory labels often specify a maximum treatment duration for acute, localized injuries, such as 7 days, before a medical review is generally recommended by official guidelines. Duration limits are in place because the risk of certain serious side effects may increase with extended use.

Q: Is Tabiflex COOL used for nerve pain, or is it only for muscle soreness?

Official documents indicate that the medication is primarily used for the relief of pain associated with localized muscle or joint injuries, such as strains or sprains. The approved indications do not typically list general neuropathic pain (nerve pain) as a specified use for this topical gel formulation.

Q: Is Tabiflex COOL considered an anti-inflammatory drug?

Yes. The active ingredient, Diclofenac, is consistently classified by health authorities as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This means it works by targeting the biological process that causes inflammation.

Q: What are the most commonly mentioned side effects of Tabiflex COOL?

The most common side effects reported are local reactions at the application site, which may include skin irritation, redness, dryness, rash, or itching. These localized reactions are usually temporary and related to the topical nature of the product.

Q: Do you get sleepy or drowsy after using Tabiflex COOL?

While the gel is applied to the skin, some of the active ingredient may be absorbed into the body. Official product monographs list central nervous system effects such as dizziness or somnolence (drowsiness) as rare or uncommon systemic side effects.

Q: Is it possible to develop a rash or itchiness from Tabiflex COOL?

Yes. The development of a local rash, itching (pruritus), and redness at the site of application are all listed in regulatory documents as common local side effects associated with the topical gel.

Q: Are there any serious side effects associated with Tabiflex COOL?

All NSAIDs, including the active ingredient in this gel, carry a risk of serious systemic events. Regulatory warnings mention a risk of serious gastrointestinal bleeding or ulceration and an increased risk of serious cardiovascular events (such as heart attack or stroke), although the risk is lower than with oral NSAIDs.

Q: Can I use Tabiflex COOL if I have a sensitive stomach?

Regulatory documents advise caution for people with a history of stomach ulcers or internal bleeding, due to the drug's classification as an NSAID. Although absorption is limited with a topical gel, a small amount does reach the system.

Q: Does Tabiflex COOL interact with common blood pressure medications?

Yes, official regulatory labels state that NSAIDs, even when used topically, may cause an impaired response to certain blood pressure medications. Regulatory documents state that blood pressure monitoring may be indicated in these situations.

Q: Are there specific foods or drinks to avoid when using Tabiflex COOL?

Official documents often caution that the risk of serious side effects, particularly stomach bleeding, may be increased by concurrent alcohol use. No specific foods are typically listed as requiring avoidance.

Q: Is Tabiflex COOL safe to use if I am also taking an over-the-counter cold medicine?

Official regulatory information advises against the concurrent use of diclofenac topical gel with other oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Many common over-the-counter cold and flu medicines contain an oral NSAID, which could increase the risk of systemic side effects.

Q: Can people over the age of 65 use Tabiflex COOL?

Regulatory documents note that use in the geriatric population (people over 65) is often associated with differences in safety and may be subject to closer monitoring in clinical settings, particularly regarding kidney and cardiovascular function.

Q: Is Tabiflex COOL suitable for teenagers?

In many jurisdictions, the official indication for diclofenac topical gel for joint problems is generally established for patients 14 years old or over. Age constraints and approved uses may vary by region and the specific strength of the product.

Q: Can people with kidney problems use Tabiflex COOL?

Official information advises against the use of topical diclofenac in patients with advanced renal disease. For patients with existing kidney impairment, official guidelines suggest renal function monitoring may be indicated for patients with existing impairment.

Q: Is there any information about Tabiflex COOL use during pregnancy?

Regulatory bodies strongly advise avoiding NSAID use starting at about 30 weeks of pregnancy due to specific risks to the developing fetus, including potential kidney and heart issues. Official information indicates that use between 20 and 30 weeks of pregnancy should be limited.

Q: Are there any known issues with Tabiflex COOL for people with asthma?

Yes. The medication is contraindicated (meaning it should not be used) in patients with aspirin-sensitive asthma. This is due to the potential for severe, potentially life-threatening allergic reactions associated with NSAIDs.

Q: Has Tabiflex COOL been studied in clinical trials?

Yes. The active ingredient, Diclofenac topical gel, has been the subject of clinical trials for its approved uses, such as treating joint pain and localized soft tissue injuries. The results of these trials form the basis of the drug's regulatory approval.

Q: Where can I find published evidence or research on Tabiflex COOL?

Official research and clinical data is typically compiled and available on government-run sites like ClinicalTrials.gov or in the clinical sections of the drug’s official regulatory label. These sites provide verified information on how the drug has been studied.

Q: What kind of research has been done on the main ingredient of Tabiflex COOL?

The research primarily focuses on the efficacy of the active ingredient, Diclofenac, as an NSAID in reducing pain and inflammation. This includes studies related to its use for localized musculoskeletal disorders and pain from osteoarthritis.

Q: Is Tabiflex COOL available without a prescription?

The regulatory status of Diclofenac topical gel depends on its concentration and the specific country. Some lower-strength formulations are classified as an over-the-counter (OTC) drug, while higher concentrations or larger package sizes may require a prescription.

Q: Can Tabiflex COOL be used for headaches or migraines?

Official regulatory labels for the topical gel formulation do not include an indication for the treatment of headaches or migraines. The product is intended for localized pain relief at the site of application.

Q: Is Tabiflex COOL habit-forming or addictive?

The active ingredient, Diclofenac, is not classified as a controlled substance by the DEA or similar bodies. Official regulatory documents do not list it as having potential for addiction or habit-forming behavior.

Q: Is it normal to feel a tingling sensation when using the product?

The cooling component often creates a distinct sensation. Furthermore, official labels sometimes list sensory disturbances at the application site, such as paresthesia (tingling or numbness), as a possible, though uncommon, effect.

Q: Does Tabiflex COOL contain any known allergens like gluten or lactose?

Official regulatory labels for the Diclofenac gel formulation typically do not list gluten or lactose in their inactive ingredients. They commonly include other excipients like isopropyl alcohol and propylene glycol, which is information relevant to people with known sensitivities.

Q: Does using Tabiflex COOL affect driving or operating machinery?

Regulatory documents advise users to be aware of potential rare systemic side effects, such as dizziness or drowsiness, that could affect the ability to drive or operate complex machinery.

Q: Can Tabiflex COOL cause stomach upset or nausea?

While systemic absorption is low with topical use, regulatory documents list gastrointestinal issues like nausea and stomach upset as possible systemic side effects. These are typically less common and less severe than those associated with taking oral NSAIDs.

Q: Is Tabiflex COOL regulated by the FDA or other health agencies?

Yes. The active ingredient, Diclofenac topical gel, is approved and regulated by governmental bodies such as the U.S. Food and Drug Administration (FDA) and similar health agencies in other countries, which ensure compliance with safety and effectiveness standards.

Q: Why do some instructions mention keeping Tabiflex COOL away from heat?

Regulatory labels specify that the product should be stored at controlled room temperature and kept away from heat and moisture. This is to maintain the drug's stability and prevent any changes that might affect its intended effectiveness or consistency.

Q: Can people with liver conditions use Tabiflex COOL?

Regulatory documents advise that liver function should be monitored during treatment. Regulatory documents list potential warning signs of liver damage (hepatotoxicity) that are relevant to users. Caution is generally advised for those with existing liver conditions.

Q: Is Tabiflex COOL considered a homeopathic remedy?

No. The product is officially classified by health regulatory bodies as a Non-Steroidal Anti-Inflammatory Drug (NSAID) based on the pharmacological action of its active ingredient, Diclofenac.

Q: Is it okay to use Tabiflex COOL if I have sensitive skin?

Official documents list local skin reactions like rash and itching as common side effects. Furthermore, the product is contraindicated for use on damaged or non-intact skin. This information is relevant for individuals with sensitive skin.

Q: Can Tabiflex COOL be used for joint pain that is not related to arthritis?

Yes. Official indications from various health agencies often include the use of the topical gel for pain associated with localized muscle and joint injuries like sprains and strains, which are not necessarily related to chronic arthritis.

Q: Does Tabiflex COOL contain alcohol?

Yes. The list of inactive ingredients for the topical gel formulation often includes isopropyl alcohol or benzyl alcohol. These ingredients are often used to help the active component dissolve and absorb into the skin.

Q: What information is available regarding long-term use of Tabiflex COOL?

Regulatory documents generally warn that the risk of serious systemic side effects, particularly cardiovascular and gastrointestinal events, may increase with the duration of use. This underscores the importance of adhering to the duration limits specified on the label.

Q: Are there any specific packaging instructions for Tabiflex COOL?

Yes. Official administration instructions often detail using the dosing card supplied within the carton to measure the correct amount of gel for each application, as a means of helping users measure the intended amount for each application.

How should Tabiflex COOL be stored and disposed of?

How to Store and Dispose of Tabiflex COOL

The storage and disposal of Tabiflex COOL (Diclofenac Diethylamine Emulsion Gel) are governed by official regulatory requirements to ensure product quality and safety.

Storage Requirements

Condition Requirement
Temperature Range Store at room temperature, generally defined as 15°C to 25°C (59°F to 77°F).
Environmental Protection The product must be protected from heat, moisture, and direct sunlight.
Container Rules Keep the product in its original container and ensure the cap is tightly closed.
Prohibited Environment The gel must not be frozen and should not be used past the printed expiry date.

Safety and Disposal

Mandatory labeling requires keeping this medicine out of the sight and reach of children.

Disposal of unused or expired Tabiflex COOL must be done according to local regulations. The product must not be disposed of via wastewater or flushed down the toilet. Recommended procedures include drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tabiflex COOL found in:

A-Z Index: